Back to today’s briefing

Story perspectives

2025 Report Unveils 11 Game-Changing Blockbuster Drugs

1/12/2025

36 3

Summary

Story summary

The 2025 Drugs to Watch report unveils eleven promising blockbuster drugs, showcasing groundbreaking therapies for obesity, cancer, and gene therapy. Notable innovations include Novo Nordisk's AWIQLI for diabetes, COBENFY for schizophrenia, and Fitusiran for hemophilia. The report underscores the transformative impact of AI in drug development, prioritizing health equity and improved patient outcomes.

1 of 1

Story summary

The 2025 Drugs to Watch report unveils eleven promising blockbuster drugs, showcasing groundbreaking therapies for obesity, cancer, and gene therapy. Notable innovations include Novo Nordisk's AWIQLI for diabetes, COBENFY for schizophrenia, and Fitusiran for hemophilia. The report underscores the transformative impact of AI in drug development, prioritizing health equity and improved patient outcomes.